Seven patients with BM were managed with a second non-PARPi modality and, although the median OS was better, this did not reach statistical significance.
← all excerpts
Description of a Retrospective Cohort of Epithelial Ovarian Cancer Patients with Brain Metastases: Evaluation of the Role of PARP Inhibitors in this Setting.
1
—
—